@article{oai:kanazawa-u.repo.nii.ac.jp:00027373,
 author = {Muraoka, Kei-ichi and Fujimoto, Koutaro and Sun, Xiangao and Yoshioka, Katsuji and Shimizu, Kou-ichi and Yagi, Masao and Bose, Jr. Henry and Miyazaki, Itsuo and Yamamoto, Ken-ichi},
 issue = {11},
 journal = {Journal of Clinical Investigation},
 month = {Jun},
 note = {FK506 is a powerful immunosuppressive drug currently in use that inhibits the activation of several transcription factors (nuclear factor (NF)-AT and NF-κB) critical for T cell activation. We show here that, contrary to the situation in T cells, FK506 activates transcription factor NF-κB in non-lymphoid cells such as fibroblasts and renal mesangial cells. We further show that FK506 induces NF-κB-regulated IL-6 production in vitro and in vivo, in particular in kidney. IL-6 has been shown previously to produce renal abnormalities in vivo, such as mesangioproliferative glomerulonephritis. Similar renal abnormalities were also observed in FK506-treated animals. These results thus suggest a causal relationship between FK506-induced NF-κB activation/IL-6 production and some of FK506-induced renal abnormalities., 金沢大学がん研究所がん分子細胞制御},
 pages = {2433--2439},
 title = {Immunosuppressant FK506 induces interleukin-6 production through the activation of transcription factor nuclear factor (NF)-κB implications for FK506 nephropathy},
 volume = {97},
 year = {1996}
}